Experimental findings suggest that granulocyte-monocyte-colony stimulating factor (GM-CSF) synergistically interacts with interleukin-2 (IL-2) in generating an efficient antigen-specific immune response. We evaluated the toxicity, antitumour activity and immunobiological effects of human recombinant (hr)-GM-CSF and hr-IL-2 in 25 cancer patients who subcutaneously (s.c.) received hr-GM-CSF 150 microg/day for 5 days, followed by hrIL-2 s.c. for 10 days and 15 days rest. Two of the most common side-effects were bone pain and fever. Of the 24 patients evaluable for response, 3 achieved partial remission, 13 experienced stable disease, and 8 progressed. Cytokine treatment increased the number of monocytes, dendritic cells (DC), and lymphocytes (memory T cells) in the peripheral blood and enhanced the antigen-specific immunoreactivity of these patients. Our results show that the hr-GM-CSF and hr-IL-2 combination is active and well tolerated. Its biological activity may support tumour associated antigen (TAA)-specific anticancer immunotherapy by increasing antigen presenting cell (APC) activity and T cell immune competence in vivo.

Correale, P., Campoccia, G., Tsang, K.y., Micheli, L., Cusi, M.G., Sabatino, M., et al. (2001). Recruitment of dendritic cells and enhanced antigen specific immune reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hrIL-2: results from a Phase Ib clinical trial. EUROPEAN JOURNAL OF CANCER, 37(7), 892-902.

Recruitment of dendritic cells and enhanced antigen specific immune reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hrIL-2: results from a Phase Ib clinical trial

MICHELI, LUCIA;CUSI, MARIA GRAZIA;FRANCINI, GUIDO
2001

Abstract

Experimental findings suggest that granulocyte-monocyte-colony stimulating factor (GM-CSF) synergistically interacts with interleukin-2 (IL-2) in generating an efficient antigen-specific immune response. We evaluated the toxicity, antitumour activity and immunobiological effects of human recombinant (hr)-GM-CSF and hr-IL-2 in 25 cancer patients who subcutaneously (s.c.) received hr-GM-CSF 150 microg/day for 5 days, followed by hrIL-2 s.c. for 10 days and 15 days rest. Two of the most common side-effects were bone pain and fever. Of the 24 patients evaluable for response, 3 achieved partial remission, 13 experienced stable disease, and 8 progressed. Cytokine treatment increased the number of monocytes, dendritic cells (DC), and lymphocytes (memory T cells) in the peripheral blood and enhanced the antigen-specific immunoreactivity of these patients. Our results show that the hr-GM-CSF and hr-IL-2 combination is active and well tolerated. Its biological activity may support tumour associated antigen (TAA)-specific anticancer immunotherapy by increasing antigen presenting cell (APC) activity and T cell immune competence in vivo.
Correale, P., Campoccia, G., Tsang, K.y., Micheli, L., Cusi, M.G., Sabatino, M., et al. (2001). Recruitment of dendritic cells and enhanced antigen specific immune reactivity in cancer patients treated with hrGM-CSF (molgramostim) and hrIL-2: results from a Phase Ib clinical trial. EUROPEAN JOURNAL OF CANCER, 37(7), 892-902.
File in questo prodotto:
File Dimensione Formato  
Recruitment of dendritic cells-Correale-2001.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 307.49 kB
Formato Adobe PDF
307.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/37356